<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01227252</url>
  </required_header>
  <id_info>
    <org_study_id>13734</org_study_id>
    <secondary_id>I4O-MC-BACB</secondary_id>
    <nct_id>NCT01227252</nct_id>
  </id_info>
  <brief_title>A Safety Study of LY2886721 Multiple Doses in Healthy Subjects</brief_title>
  <official_title>Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of
      LY2886721 multiple doses, how the body handles the drug, and the drug's effect on the body.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Effects</measure>
    <time_frame>Predose up to Day 70</time_frame>
    <description>Clinically significant effects were defined as serious and nonserious adverse events. A summary of serious and all other nonserious adverse events is located in the Reported Adverse Event module. The number of participants with at least 1 adverse event in each treatment arm is reported for this outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Maximum Observed Drug Concentration at Steady State (Cmax,ss) of LY2886721</measure>
    <time_frame>Predose (Day 14) up to Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Area Under the Concentration Versus Time Curve (AUC) of LY2886721</measure>
    <time_frame>Predose (Day 14) to 24 Hours post-dose (Day 15)</time_frame>
    <description>Area under the concentration versus time curve during 1 dosing interval (1 dosing interval=24 hours) at steady state (AUCτ,ss) is being reported for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Amyloid Beta (Aβ) 1-40 Concentration</measure>
    <time_frame>Predose (Day 14) up to Day 19</time_frame>
    <description>The minimum concentration (Cnadir) is being reported for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal Fluid (CSF) Concentration of LY2886721</measure>
    <time_frame>24 Hours post-dose (Day 15)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 15 Endpoint in Cerebrospinal Fluid (CSF) Amyloid Beta (Aβ) 1-40 Concentration</measure>
    <time_frame>Predose (Day 14), 24 Hours post-dose (Day 15)</time_frame>
    <description>The Least Squares means were adjusted for baseline concentration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>LY2886721</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2886721</intervention_name>
    <description>5 milligrams (mg) up to 35 mg, administered orally as capsules, daily for 14 days</description>
    <arm_group_label>LY2886721</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally as capsules, daily for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and non-childbearing potential women

          -  Body mass index between 18.0-32.0 kilograms per square meter (kg/m^2)

          -  Are reliable and willing to make yourself available for the duration of the study and
             are willing to follow study procedures and research unit policies

        Exclusion Criteria:

          -  Taking over-the-counter or prescription medication with the exception of vitamins or
             minerals

          -  Smoke more than 10 cigarettes per day

          -  Drink more than 5 cups of caffeine containing beverages (for example, coffee, tea) per
             day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>October 21, 2010</study_first_submitted>
  <study_first_submitted_qc>October 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2010</study_first_posted>
  <results_first_submitted>May 9, 2019</results_first_submitted>
  <results_first_submitted_qc>May 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 19, 2019</results_first_posted>
  <last_update_submitted>May 9, 2019</last_update_submitted>
  <last_update_submitted_qc>May 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo was administered orally as capsules, once daily for 14 days.</description>
        </group>
        <group group_id="P2">
          <title>5 mg LY2886721</title>
          <description>A 5-milligram (mg) dose of LY2886721 was administered orally as capsules, once daily for 14 days.</description>
        </group>
        <group group_id="P3">
          <title>15 mg LY2886721</title>
          <description>A 15-mg dose of LY2886721 was administered orally as capsules, once daily for 14 days.</description>
        </group>
        <group group_id="P4">
          <title>35 mg LY2886721</title>
          <description>A 35-mg dose of LY2886721 was administered orally as capsules, once daily for 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo was administered orally as capsules, once daily for 14 days.</description>
        </group>
        <group group_id="B2">
          <title>5 mg LY2886721</title>
          <description>A 5-milligram (mg) dose of LY2886721 was administered orally as capsules, once daily for 14 days.</description>
        </group>
        <group group_id="B3">
          <title>15 mg LY2886721</title>
          <description>A 15-mg dose of LY2886721 was administered orally as capsules, once daily for 14 days.</description>
        </group>
        <group group_id="B4">
          <title>35 mg LY2886721</title>
          <description>A 35-mg dose of LY2886721 was administered orally as capsules, once daily for 14 days.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Effects</title>
        <description>Clinically significant effects were defined as serious and nonserious adverse events. A summary of serious and all other nonserious adverse events is located in the Reported Adverse Event module. The number of participants with at least 1 adverse event in each treatment arm is reported for this outcome measure.</description>
        <time_frame>Predose up to Day 70</time_frame>
        <population>All randomized participants were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered orally as capsules, once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>5 mg LY2886721</title>
            <description>A 5-milligram (mg) dose of LY2886721 was administered orally as capsules, once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>15 mg LY2886721</title>
            <description>A 15-mg dose of LY2886721 was administered orally as capsules, once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>35 mg LY2886721</title>
            <description>A 35-mg dose of LY2886721 was administered orally as capsules, once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Effects</title>
          <description>Clinically significant effects were defined as serious and nonserious adverse events. A summary of serious and all other nonserious adverse events is located in the Reported Adverse Event module. The number of participants with at least 1 adverse event in each treatment arm is reported for this outcome measure.</description>
          <population>All randomized participants were included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nonserious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Maximum Observed Drug Concentration at Steady State (Cmax,ss) of LY2886721</title>
        <time_frame>Predose (Day 14) up to Day 19</time_frame>
        <population>All participants who received study drug on Day 14 and had evaluable pharmacokinetic data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg LY2886721</title>
            <description>Participants received a 5-mg oral dose of LY2886721 capsules, once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>15 mg LY2886721</title>
            <description>Participants received a 10-mg oral dose of LY2886721 capsules, once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>35 mg LY2886721</title>
            <description>Participants received a 35-mg oral dose of LY2886721 capsules, once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Maximum Observed Drug Concentration at Steady State (Cmax,ss) of LY2886721</title>
          <population>All participants who received study drug on Day 14 and had evaluable pharmacokinetic data were included in the analysis.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="48"/>
                    <measurement group_id="O2" value="43.0" spread="24"/>
                    <measurement group_id="O3" value="80.0" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Area Under the Concentration Versus Time Curve (AUC) of LY2886721</title>
        <description>Area under the concentration versus time curve during 1 dosing interval (1 dosing interval=24 hours) at steady state (AUCτ,ss) is being reported for this outcome measure.</description>
        <time_frame>Predose (Day 14) to 24 Hours post-dose (Day 15)</time_frame>
        <population>All participants who received study drug on Day 14 and had evaluable pharmacokinetic data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg LY2886721</title>
            <description>Participants received a 5-mg oral dose of LY2886721 capsules, once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>15 mg LY2886721</title>
            <description>Participants received a 10-mg oral dose of LY2886721 capsules, once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>35 mg LY2886721</title>
            <description>Participants received a 35-mg oral dose of LY2886721 capsules, once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Area Under the Concentration Versus Time Curve (AUC) of LY2886721</title>
          <description>Area under the concentration versus time curve during 1 dosing interval (1 dosing interval=24 hours) at steady state (AUCτ,ss) is being reported for this outcome measure.</description>
          <population>All participants who received study drug on Day 14 and had evaluable pharmacokinetic data were included in the analysis.</population>
          <units>nanogram*hour per milliliter (ng*h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" spread="41"/>
                    <measurement group_id="O2" value="447" spread="23"/>
                    <measurement group_id="O3" value="861" spread="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Amyloid Beta (Aβ) 1-40 Concentration</title>
        <description>The minimum concentration (Cnadir) is being reported for this outcome measure.</description>
        <time_frame>Predose (Day 14) up to Day 19</time_frame>
        <population>All participants who received study drug on Day 14 and had evaluable pharmacodynamic data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered orally as capsules, once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>5 mg LY2886721</title>
            <description>A 5-milligram (mg) dose of LY2886721 was administered orally as capsules, once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>15 mg LY2886721</title>
            <description>A 15-mg dose of LY2886721 was administered orally as capsules, once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>35 mg LY2886721</title>
            <description>A 35-mg dose of LY2886721 was administered orally as capsules, once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Amyloid Beta (Aβ) 1-40 Concentration</title>
          <description>The minimum concentration (Cnadir) is being reported for this outcome measure.</description>
          <population>All participants who received study drug on Day 14 and had evaluable pharmacodynamic data were included in the analysis.</population>
          <units>picogram per milliliter (pg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123" spread="14.5"/>
                    <measurement group_id="O2" value="49" spread="55.1"/>
                    <measurement group_id="O3" value="40" spread="19.7"/>
                    <measurement group_id="O4" value="25" spread="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebrospinal Fluid (CSF) Concentration of LY2886721</title>
        <time_frame>24 Hours post-dose (Day 15)</time_frame>
        <population>A subset of all participants who received study drug on Day 14 and had evaluable pharmacodynamic data was included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg LY2886721</title>
            <description>Participants received a 5-mg oral dose of LY2886721 capsules, once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>15 mg LY2886721</title>
            <description>Participants received a 10-mg oral dose of LY2886721 capsules, once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>35 mg LY2886721</title>
            <description>Participants received a 35-mg oral dose of LY2886721 capsules, once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebrospinal Fluid (CSF) Concentration of LY2886721</title>
          <population>A subset of all participants who received study drug on Day 14 and had evaluable pharmacodynamic data was included in the analysis.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="64.5"/>
                    <measurement group_id="O2" value="1.4" spread="16.6"/>
                    <measurement group_id="O3" value="3.8" spread="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 15 Endpoint in Cerebrospinal Fluid (CSF) Amyloid Beta (Aβ) 1-40 Concentration</title>
        <description>The Least Squares means were adjusted for baseline concentration.</description>
        <time_frame>Predose (Day 14), 24 Hours post-dose (Day 15)</time_frame>
        <population>All participants who received study drug on Day 14 and had evaluable pharmacodynamic data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered orally as capsules, once daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>5 mg LY2886721</title>
            <description>A 5-milligram (mg) dose of LY2886721 was administered orally as capsules, once daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>15 mg LY2886721</title>
            <description>A 15-mg dose of LY2886721 was administered orally as capsules, once daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>35 mg LY2886721</title>
            <description>A 35-mg dose of LY2886721 was administered orally as capsules, once daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 15 Endpoint in Cerebrospinal Fluid (CSF) Amyloid Beta (Aβ) 1-40 Concentration</title>
          <description>The Least Squares means were adjusted for baseline concentration.</description>
          <population>All participants who received study drug on Day 14 and had evaluable pharmacodynamic data were included in the analysis.</population>
          <units>percent change (%)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" lower_limit="-9.1" upper_limit="1.3"/>
                    <measurement group_id="O2" value="-11.8" lower_limit="-16.1" upper_limit="-7.4"/>
                    <measurement group_id="O3" value="-27.5" lower_limit="-31.6" upper_limit="-23.5"/>
                    <measurement group_id="O4" value="-59.1" lower_limit="-67.0" upper_limit="-51.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo was administered orally as capsules, once daily for 14 days.</description>
        </group>
        <group group_id="E2">
          <title>5 mg LY2886721</title>
          <description>A 5-milligram (mg) dose of LY2886721 was administered orally as capsules, once daily for 14 days.</description>
        </group>
        <group group_id="E3">
          <title>15 mg LY2886721</title>
          <description>A 15-mg dose of LY2886721 was administered orally as capsules, once daily for 14 days.</description>
        </group>
        <group group_id="E4">
          <title>35 mg LY2886721</title>
          <description>A 35-mg dose of LY2886721 was administered orally as capsules, once daily for 14 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Visual field tests abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

